丹参川芎嗪与依达拉奉联合用药方案治疗急性脑梗死的临床效果

The clinical effect of salvia miltiorrhiza ligustrazine combined with edaravone in the treatment of acute cerebral infarction

目的:就急性脑梗死(acute cerebral infarction,ACI)患者在治疗的过程之中实施丹参川芎嗪与依达拉奉联合用药,并就联合用药的有效性和安全性进行分析。方法:选择浑南区中心医院收治的病发急性脑梗死患者162例,接收患者时间段为2019年1月至2020年12月,随机开展规范的分组操作。对照组针对所纳入的81例单用依达拉奉给药方案,观察组所纳入的81例在采用依达拉奉基础上加用丹参川芎嗪。对比两组临床治疗总有效率、用药不良反应发生率,对比两组治疗前后神经功能缺损(NIHSS)评分。结果:经对观察组所纳入的患者总有效率高于对照组评定数据(P<0.05)。在对两组用药不良反应发生率指标进行的测定中,差异不明显(P>0.05)。在各项治疗工作实施前,经对两组所表现出的NIHSS评分展开测定,差异不明显(P>0.05),在各项治疗工作实施后,经对NIHSS评分测定值进行评测,两组均呈降低显示,且观察组变化更为突出(P<0.05)。结论:对ACI患者应用丹参川芎嗪与依达拉奉联合用药方案治疗效果显著,可有效改善患者神经功能缺损状况,促进患者康复,且用药不良反应少,治疗安全性高,值得应用。

Objective:To treat patients with acute cerebral infarction(ACI)with the combination of salvia miltiorrhiza ligustrazine and edaravone,and to analyze the effectiveness and safety of the combination.Methods:A total of 162 patients with acute cerebral infarction in Hunnan District Central Hospital from January 2019 to December 2020 were enrolled in this study.The patients were randomly divided into two groups.81 cases in the control group were treated with edaravone alone,while 81 cases in the observation group were treated with salvia miltiorrhiza ligustrazine based on edaravone.The total effective rate of clinical treatment and the incidence of adverse drug reactions were compared between the two groups.The neurological deficit(NIHSS)scores before and after treatment were compared between the two groups.Results:The total effective rate of patients in the observation group was higher than that in the control group(P<0.05).In the measurement of the incidence of adverse drug reactions,there was no significant difference(P>0.05).Before the implementation of various treatments,the NIHSS scores of the two groups showed no significant difference(P>0.05).After the implementation of various treatments,the NIHSS scores showed a decrease,and the changes in the observation group were more prominent(P<0.05).Conclusion:The combination of Salvia Miltiorrhiza Ligustrazine and Edaravone is effective in the treatment of ACI patients,which can effectively improve the neurological deficit and promote the recovery of patients,with few adverse drug reactions and high treatment safety,and is worthy of application.